World News

The plant is scheduled to begin operations by 2029 and will focus on producing cutting-edge treatments for metabolic conditions, particularly obesity medications.

Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

This collaboration delivers crucial funding to Agenus while simultaneously securing sustained biologics manufacturing capacity within the United States.

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

The company plans to bring Neopak Glass Prefillable Syringe production to its long-established facility in Columbus, Nebraska.